"Monitoring of therapy progress in patients with gynecological tumor disease or breast cancer using peripheral biomarkers"

"Monitoring of therapy progress in patients with gynecological tumor disease or breast cancer using peripheral biomarkers" - MoMaGyn

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023293

Enrollment

500

Registered

2020-10-29

Start date

2020-11-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Ovarian cancer Endometrial cancer Cervical Cancer Vulvar cancer Vaginal Cancer C51-C58 C50

Interventions

Group 1: Every patient with the initial diagnosis of a gynaeco-oncological disease who presents herself at the Gynaecological Clinic of the Hanau Clinic is asked to participate in this examination. If

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Coming of age - Proven gynecological malignant disease

Exclusion criteria

Exclusion criteria: - patients under 18 years - patients not being contractually capable - patients without existing written consent - patients who recanted their written consent - clinically apparent anemia

Design outcomes

Primary

Measure	Time frame
The primary goal is the investigation of new tumor markers or multiplex assays for various malignant diseases. The advised number of patients is for: - Breast cancer 200 - 250 patients, each with a complete sample series - Ovarian cancer ~ 50 patients with one complete sample series each And for other gynecological malignancies (endometrium / cervical / vulvar / vagina) about 20 - 30 per entity. The collection period is initially limited to 24 months, but can be extended until the target is reached if the notified number of samples is not reached.	—

Measure

Time frame

The primary goal is the investigation of new tumor markers or multiplex assays for various malignant diseases. The advised number of patients is for: - Breast cancer 200 - 250 patients, each with a complete sample series - Ovarian cancer ~ 50 patients with one complete sample series each And for other gynecological malignancies (endometrium / cervical / vulvar / vagina) about 20 - 30 per entity. The collection period is initially limited to 24 months, but can be extended until the target is reached if the notified number of samples is not reached.

—

Secondary

Measure	Time frame
no secondary outcome	—

Countries

Germany

Contacts

Public ContactNicole Hänse

Klinkum Hanau - Frauenklinik

nicole_haense@klinikum-hanau.de06181 - 2962510

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026